235 Preclinical evaluation and anti-tumor activity of AZD6422, a CLDN18.2 targeting armored CAR-T for gastric, esophageal and pancreatic cancers by Mark Cobbold, Nicolas Giraldo, Gordon Moody, Allison Barrett, Jean-Martin Lapointe, Shannon Breen, Rosa Carrasco, Zachary Britton, Benjamin Clark, Maria AS Broggi, Bala NN Rao Attili, Amy Hatke, Christina Grigoriadou, Melissa Damschroder, Emily Bosco

1169 AZD5863: a specific, potent, affinity-optimized claudin 18.2 and CD3 binding T cell-engager that elicits low cytokine release and is capable of bystander killing by Rakesh Kumar, Yun He, Simon Dovedi, Mark Cobbold, Kristen Pollizzi, Saso Cemerski, Scott Hammond, Marina Natoli, Yiping Rong, Jonathan Fitzgerald, Mary McFarlane, Kathy Mulgrew, Miguel Gaspar, Christopher Lloyd, Douglas C Palmer, Maria AS Broggi, Laure Castan, Sharif Rahmy, Cathryn Kelton, Martin Korade, Oisin Huhn, D Gareth Rees, Anna Sigurdardottir, Benjamin Ridgway, Kathryn Ball, Fred Arce Vargas, Natalia Ceaicovscaia, Gayle Pouliot, Philip Szekeres